Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Department of Urology, Mayo Clinic, Rochester, MN, USA.
Nat Rev Urol. 2022 May;19(5):263-279. doi: 10.1038/s41585-022-00575-4. Epub 2022 Mar 8.
Measuring treatment-related quality of life (QOL) has become an increasingly requisite component of delivering high-quality care for patients with prostate cancer. Patient-reported outcome measures (PROMs) have, therefore, become an important tool for understanding the adverse effects of radical prostate cancer treatment and have been widely integrated into clinical practice. By providing real-time symptom monitoring and improved clinical feedback to patients and providers, PRO assessment has led to meaningful gains in prostate cancer care delivery and quality improvement worldwide. By providing an avenue for benchmarking, collaboration and population health monitoring, PROMs have delivered substantial improvements beyond providing individual symptom feedback. However, multilevel barriers exist that need to be addressed before the routine implementation of PROMs is achieved. Improvements in collection, interpretation, standardization and reporting will be crucial for the continued implementation of PROM instruments in prostate cancer pathways.
测量与治疗相关的生活质量(QOL)已成为为前列腺癌患者提供高质量护理的必要组成部分。因此,患者报告的结果测量(PROM)已成为了解前列腺癌根治性治疗不良影响的重要工具,并已广泛纳入临床实践。通过为患者和提供者提供实时症状监测和改善的临床反馈,PRO 评估已在全球范围内为前列腺癌护理提供和质量改进带来了有意义的收益。通过为基准测试、协作和人群健康监测提供途径,PROM 除了提供个体症状反馈之外,还带来了实质性的改进。然而,在实现 PROM 的常规实施之前,还存在需要解决的多层次障碍。在前列腺癌路径中继续实施 PROM 工具,收集、解释、标准化和报告的改进将至关重要。